However, there is a lack of serum biomarkers for identifying LVDD in high-risk individuals, as conventional heart failure-related biomarkers, such as serum brain natriuretic peptides (BNP), typically remain within the normal range during the early stages of HF. This evidence concerns the gene NPPB and heart failure.